Publication

Article

BioPharm International

BioPharm International-06-15-2016
Volume2016 ebook
Issue 1
Pages: 22–28

Regulatory Reform in China: Implications for Global Biopharmaceutical Companies

Author(s):

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China. To compete in this resource-intensive manufacturing process that requires large volume capacity and a technically trained labor force, it is logical pharmaceutical companies will turn to contract manufacturing in China to meet strategic sourcing requirements.

Download the

BioPharm International 2016 Outsourcing Resources eBook

.

 

 

 

 

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.